Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy

(2014) Min Geun Lee et al.   CHEMOTHERAPY

A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer

(2013) Naminatsu Takahara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

(2013) Hideki Ueno et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma

(2012) Marco La Torre et al.   ANNALS OF SURGICAL ONCOLOGY

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

(2011) M J Proctor et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients

(2011) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

(2011) Uwe Pelzer et al.   EUROPEAN JOURNAL OF CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

(2011) Elias Assaf et al.   ONCOLOGY

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

(2010) Kentaro Sudo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic Cancer

(2010) Mitsugi Shimoda et al.   CHEMOTHERAPY

S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure

(2010) A. Todaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

(2008) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY